{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"34.7","upperLimit":"48.1","value":"41"},{"groupId":"OG001","lowerLimit":"26.5","upperLimit":"45.4","value":"36"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"218"},{"groupId":"OG001","value":"107"}],"units":"Participants"}],"description":"Overall Response Rate is defined as the percentage of participants with a confirmed partial response (PR) or better (i.e., PR, very good partial response \\[VGPR\\], complete response \\[CR\\] and stringent complete response \\[sCR\\]), according to the International Myeloma Working Group (IMWG) Response Criteria. PR: ≥50% reduction of serum M-protein and reduction in 24-hour (h) urinary M-protein by ≥90% or to \\<200 mg/24-h; VGPR: serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \\<100 mg/24-h; CR:negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \\<5% plasmacytomas in the bone marrow; sCR:stringent complete response, CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with relapsed/refractory multiple myeloma (RRMM) received 30 minutes intravenous infusion of 2.5 milligram/kilogram (mg/kg) belantamab mafodotin on day 1 of each 21-day cycle","id":"OG000","title":"Belantamab Mafodotin"},{"description":"Participants with RRMM received 4 mg pomalidomide capsule daily on Days 1 to 21 of each 28-day cycle, along with 40 mg or at lower 20 mg (for participants \\>75 years of age) dose of dexamethasone tablet once weekly (Days 1, 8, 15 and 22)","id":"OG001","title":"Pomalidomide Plus Dexamethasone"}],"paramType":"NUMBER","populationDescription":"ITT Population","reportingStatus":"POSTED","timeFrame":"Up to approximately 263 weeks","title":"Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}